1,2-bis(triethoxysilyl)ethane is an organosilicon compound used as a precursor to polysiloxanes. It is a colorless liquid that is soluble in most organic solvents. The synthesis of 1,2-bis(triethoxysilyl)ethane involves the reaction of 1,2-dichloroethane with triethoxysilane in the presence of a catalyst, such as magnesium or zinc. The resulting product is then purified by distillation. 1,2-bis(triethoxysilyl)ethane is important because it can be used to prepare a variety of polysiloxanes, which have a wide range of applications, including as sealants, adhesives, coatings, and elastomers. 1,2-bis(triethoxysilyl)ethane is also studied for its potential use in the synthesis of new materials with improved properties. For example, it has been used to prepare siloxane-based polymers with enhanced thermal stability and mechanical strength. 1,2-bis(triethoxysilyl)ethane is also being investigated for its potential use in the development of new biocompatible materials.'
```
| ID Source | ID |
|---|---|
| PubMed CID | 85266 |
| SCHEMBL ID | 35088 |
| MeSH ID | M0504415 |
| Synonym |
|---|
| 1,2-bis(triethoxysilyl)ethane , |
| f57b935g98 , |
| unii-f57b935g98 |
| AKOS008901180 |
| 3,8-dioxa-4,7-disiladecane, 4,4,7,7-tetraethoxy- |
| einecs 240-212-2 |
| 4,4,7,7-tetraethoxy-3,8-dioxa-4,7-disiladecane |
| 1,2-bis(triethoxysilyl)ethane, 96% |
| 16068-37-4 |
| triethoxy(2-triethoxysilylethyl)silane |
| FT-0606318 |
| S02108 |
| 1,1,1,4,4,4-hexaethoxy-1,4-disilabutane |
| SCHEMBL35088 |
| ethylenebis(triethoxysilane) |
| IZRJPHXTEXTLHY-UHFFFAOYSA-N |
| DTXSID7051763 |
| 1,2-bis(triethoxysilyl)ethane, |
| B4123 |
| c14h34o6si2 |
| mfcd00239362 |
| DS-7374 |
| SY041901 |
| AC1864 |
| CS-W013899 |
| Q27277656 |
| A883191 |
| 1,2-bis(triethoxysilyl)ethane, 95% |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (31.25) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||